Skip to content
10-Q

Quarterly Report

Nugenerex Immuno-oncology, Inc.

0001607062-21-000045

← back to feed
Filed
Mar 12, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2021 · Mar 12, 2021 100.3M sh
Stockholders Equity Q2 2021 · Jan 31, 2021 −$6.61M
Stockholders Equity Q2 2021 · Oct 31, 2020 −$6.01M
Stockholders Equity Q2 2021 · Jul 31, 2020 −$5.84M
Stockholders Equity Q2 2021 · Jan 31, 2020 −$5.13M
Stockholders Equity Q2 2021 · Oct 31, 2019 −$4.84M
Stockholders Equity Q2 2021 · Jul 31, 2019 −$4.38M
Current Liabilities Q2 2021 · Jan 31, 2021 $8.41M
Current Liabilities Q2 2021 · Jul 31, 2020 $5.84M
Current Assets Q2 2021 · Jan 31, 2021 $1.8M
Current Assets Q2 2021 · Jul 31, 2020 $84
Sga Expense Q2 2021 · Jan 31, 2021 $494.18K
Sga Expense Q2 2021 · Jan 31, 2021 $1.1M
Sga Expense Q2 2021 · Jan 31, 2020 $80.05K
Sga Expense Q2 2021 · Jan 31, 2020 $111.85K
Rd Expense Q2 2021 · Jan 31, 2021 $1.34M
Rd Expense Q2 2021 · Jan 31, 2021 $2.23M
Rd Expense Q2 2021 · Jan 31, 2020 $3.5K
Rd Expense Q2 2021 · Jan 31, 2020 $255.27K
Net Income Q2 2021 · Jan 31, 2021 −$2.08M
Net Income Q2 2021 · Jan 31, 2021 −$3.82M
Net Income Q2 2021 · Jan 31, 2020 −$292.37K
Net Income Q2 2021 · Jan 31, 2020 −$775.63K
Operating Income Q2 2021 · Jan 31, 2021 −$1.83M
Operating Income Q2 2021 · Jan 31, 2021 −$3.33M
Operating Income Q2 2021 · Jan 31, 2020 −$83.55K
Operating Income Q2 2021 · Jan 31, 2020 −$367.12K